The DOI matches its Crossref record.
Biochemical characterization of a beta-lactamase that hydrolyzes penems and carbapenems from two Serratia marcescens isolates
Open accessAbstract
Reexamination of Serratia marcescens isolates obtained in 1982 revealed two organisms that were resistant to the penem FCE 22101 (MIC, 512 micrograms/ml) and imipenem (MIC, 16 micrograms/ml) and that had slightly reduced susceptibilities to meropenem (MIC, 0.12 micrograms/ml). MICs of these agents for typical S. marcescens isolates were 1 to 8, 0.25 to 0.5, and 0.03 micrograms/ml, respectively. The two isolates were fully susceptible to broad-spectrum cephalosporins, and only one was highly resistant to ampicillin and carbenicillin (MICs, greater than 1,024 micrograms/ml). Both isolates had beta-lactamases that focused at pIs 8.2 and 9.7. The penicillin-resistant isolate additionally produced the TEM-1 enzyme. The enzymes with pIs of 8.2 and 9.7 were separated by cation-exchange chromatography. The pI 8.2 beta-lactamase was a class I enzyme of the type found in most S. marcescens isolates. It was almost inactive against carbapenems and penems, as was the class I enzyme from another S. marcescens strain. The pI 9.7 enzyme hydrolyzed penems and carbapenems rapidly: kcat (turnover number) values for FCE 22101, imipenem, and meropenem were 3.4, 26, and 1% of the kcat value for cephaloridine, respectively; kcat/Km values were 140, 915, and 150% of the kcat/Km value for cephaloridine, respectively. Otherwise, the pI 9.7 enzyme had predominantly penicillinase activity. It was inhibited more readily by clavulanate than by tazobactam and was inactivated by the chelating agents EDTA and ethylene glycol-bis(beta-aminoethyl ether)-N,N,N',N'-tetraacetic acid. Expression of the pI 9.7 enzyme was not associated with any plasmid, and production was not transferred to Escherichia coli K-12 recipients, even after the mobilizing plasmid pUZ8 was inserted into the S. marcecens donor strains.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Carbapenemases: the Versatile β-Lactamases
Queenan, A. M., & Bush, K. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00001-07 · Cited by 2,499
A functional classification scheme for beta-lactamases and its correlation with molecular structure
Bush, K., Jacoby, G. A., & Medeiros, A. A. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.6.1211 · Cited by 2,475
beta-Lactamases in laboratory and clinical resistance
Livermore, D. M. (1995) · Clinical Microbiology Reviews · doi:10.1128/cmr.8.4.557 · Cited by 1,779
Self-citationThree Decades of β-Lactamase Inhibitors
Drawz, S. M., & Bonomo, R. A. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00037-09 · Cited by 1,709
Metallo-β-Lactamases: the Quiet before the Storm?
Walsh, T. R., Toleman, M. A., Poirel, L., & Nordmann, P. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.2.306-325.2005 · Cited by 1,431
Carbapenem resistance in Enterobacteriaceae: here is the storm!
Nordmann, P., Dortet, L., & Poirel, L. (2012) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2012.03.003 · Cited by 1,038
Epidemiology of β-Lactamase-Producing Pathogens
Bush, K., & Bradford, P. A. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00047-19 · Cited by 938
Past and Present Perspectives on β-Lactamases
Bush, K. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01076-18 · Cited by 832
Emerging carbapenemases in Gram-negative aerobes
Nordmann, P., & Poirel, L. (2002) · Clinical Microbiology and Infection · doi:10.1046/j.1469-0691.2002.00401.x · Cited by 684
Serratia Infections: from Military Experiments to Current Practice
Mahlen, S. D. (2011) · Clinical Microbiology Reviews · doi:10.1128/cmr.00017-11 · Cited by 627
Walther-Rasmussen, J., & Høiby, N. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki482 · Cited by 495
Carfi, A., Pares, S., Duée, E., Galleni, M., Duez, C., Frère, J. M., & Dideberg, O. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00174.x · Cited by 459
Woodford, N., Tierno, P. M., Young, K., Tysall, L., Palepou, M.-F. I., Ward, E., Painter, R. E., Suber, D. F., Shungu, D., Silver, L. L., et al. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.12.4793-4799.2004 · Cited by 442
Self-citationOsano, E., Arakawa, Y., Wacharotayankun, R., Ohta, M., Horii, T., Ito, H., Yoshimura, F., & Kato, N. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.1.71 · Cited by 440
“Stormy waters ahead”: global emergence of carbapenemases
Patel, G., & Bonomo, R. A. (2013) · Frontiers in Microbiology · doi:10.3389/fmicb.2013.00048 · Cited by 423
The rapid spread of carbapenem-resistant Enterobacteriaceae
Potter, R. F., D’Souza, A. W., & Dantas, G. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.09.002 · Cited by 403
Carbapenem-hydrolyzing beta-lactamases
Rasmussen, B. A., & Bush, K. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.2.223 · Cited by 361
Tackling Threats and Future Problems of Multidrug-Resistant Bacteria
Medina, E., & Pieper, D. H. (2016) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2016_492 · Cited by 356
Carbapenemases: a problem in waiting?
Livermore, D. M., & Woodford, N. (2000) · Current Opinion in Microbiology · doi:10.1016/s1369-5274(00)00128-4 · Cited by 323
Self-citationNew Mechanisms of Bacterial Resistance to Antimicrobial Agents
Epstein, F. H., Jacoby, G. A., & Archer, G. L. (1991) · New England Journal of Medicine · doi:10.1056/nejm199102283240906 · Cited by 312
Carbapenemases: Molecular Diversity and Clinical Consequences
Poirel, L., Pitout, J. D., & Nordmann, P. (2007) · Future Microbiology · doi:10.2217/17460913.2.5.501 · Cited by 309
Hammoudi Halat, D., & Ayoub Moubareck, C. (2020) · Antibiotics · doi:10.3390/antibiotics9040186 · Cited by 287
Kinetic interactions of tazobactam with beta-lactamases from all major structural classes
Bush, K., Macalintal, C., Rasmussen, B. A., Lee, V. J., & Yang, Y. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.4.851 · Cited by 274
Self-citationWalther-Rasmussen, J., & Høiby, N. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm226 · Cited by 271
Ito, H., Arakawa, Y., Ohsuka, S., Wacharotayankun, R., Kato, N., & Ohta, M. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.4.824 · Cited by 266
Beta‐lactamases and bacterial resistance to antibiotics
Frère, J. (1995) · Molecular Microbiology · doi:10.1111/j.1365-2958.1995.tb02404.x · Cited by 263
The ABCD’s of β-lactamase nomenclature
Bush, K. (2013) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-013-0640-7 · Cited by 239
Trends in β‐Lactam Resistance Among Enterobacteriaceae
Nordmann, P. (1998) · Clinical Infectious Diseases · doi:10.1086/514905 · Cited by 124
Metadata
- Authors
- Yang, Y. J., Wu, P. J., & Livermore, D. M.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 1990-05
- Volume
- 34
- Issue
- 5
- Pages
- 755-758
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W1983054660
- Cited by
- 163
- References
- 0
- FWCI
- 4.39
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.